
Railcare - Targeting double digit grow rate

Redeye was hoping for a stronger finish to 2022 in terms of earnings. The dip in Q4 is however most likely very temporary. We find Railcare's new financial sales target to be ambitious and realistic and quite in line with our mid-term assumptions. Our forecasts and valuation remain virtually unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Railcare - Targeting double digit grow rate